Rabies vaccine inactivated (VRVg) - Sanofi

Drug Profile

Rabies vaccine inactivated (VRVg) - Sanofi

Alternative Names: Purified Vero Rabies Vaccine - Sanofi; Rabies VRVg; VerorabVax; VRVg 1; VRVg 2

Latest Information Update: 06 Jun 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rabies

Most Recent Events

  • 06 Jun 2017 No recent reports on development identified - Preregistration for Rabies (Prevention) in China (IM)
  • 17 Apr 2017 Sanofi initiates enrolment in a phase II trial for Rabies (In volunteers) in USA (NCT03145766)
  • 31 Dec 2015 Sanofi completes a phase II trial for Rabies (prevention) in USA (NCT01784874)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top